NCT00511173

Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm

Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist's Dosing

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 102 (actual)
• Sponsor: Creighton University · Academic / Other
• Sex: All
• Age: 19 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective comparison of clinician dosing and a pharmacogenetic algorithm in diagnosed patients requiring warfarin therapy.

Detailed description

Diagnosed patients with atrial fibrillation, pulmonary embolism, or deep venous thrombosis requiring warfarin therapy will be consented and a tube of blood for DNA analysis will be drawn. The clinician dosing group will not be eligible to obtain the pharmacogenetic results and the algorithm group will have their warfarin pharmacogenetic SNPs performed and integrated into the algorithm and the warfarin dose will be calculated. Outcomes of patients receiving both methods will be gathered and statistically analyzed.

Conditions

• Atrial Fibrillation
• Pulmonary Embolism
• Deep Vein Thrombosis

Interventions

Type	Name	Description
GENETIC	Warfarin Dose based on pharmacogenetics	Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm

Timeline

• Start date: 2006-08-01
• Primary completion: 2008-11-01
• Completion: 2008-11-01
• First posted: 2007-08-03
• Last updated: 2012-12-11
• Results posted: 2012-12-11